Medical and Pharmaceutical Nuvation Bio scoops US$250M financing to launch promising lung cancer therapeutic Taletrectinib is the most advanced drug in the company's pipeline Rowan DunneMarch 4, 2025
Medical and Pharmaceutical TG Therapeutics stock spikes on strong financials and optimism for its flagship drug The company's product for relapsing forms of multiple sclerosis (RMS), is its primary source of its most recent success Joseph MortonMarch 3, 2025
Medical and Pharmaceutical Medtronic explores global options to escape Trump tariffs Trump imposed 25 per cent duties on imports from Mexico and Canada, set to take effect in March Joseph MortonFebruary 26, 2025
Medical and Pharmaceutical Poor people die of cancer more than rich: UK research Nearly half of the 28,400 additional cancer deaths linked to deprivation are due to lung cancer Joseph MortonFebruary 24, 2025
Medical and Pharmaceutical Pulmonx Corporation shares spike on record-breaking Q4 revenue Pulmonx achieved USD$83.8 million in worldwide revenue, reflecting a robust 22 per cent growth over 2023 Joseph MortonFebruary 21, 2025
Medical and Pharmaceutical New Korean cancer tech finds mutations with only a few drops of blood In a clinical trial with blood from 83 patients, the test identified 100 per cent of EGFR gene mutations Joseph MortonFebruary 18, 2025
Medical and Pharmaceutical Early lung cancer diagnosis saves 52-year-old Indian man’s life A persistent cough and breathlessness while climbing stairs prompted him to visit the hospital Rowan DunneFebruary 13, 2025
Medical and Pharmaceutical PEI needs to jump on lung cancer screening bandwagon ASAP, advocate says It is the last Canadian province without a program for catching the disease Rowan DunneFebruary 10, 2025
Medical and Pharmaceutical British scientists develop lung cancer blood test that gives results in 40 minutes This new screening device is the product of a 3-year study from Cranfield University scholars Rowan DunneFebruary 7, 2025
Medical and Pharmaceutical Lipella Pharmaceuticals skyrockets on FDA access approval for mouth disease treatment The stock was up by about 200% during early trading hours Rowan DunneFebruary 6, 2025